Fate Therapeutics (FATE) EBT Margin Growth (3y) (2015 - 2026)

Fate Therapeutics (FATE) EBT Margin Growth (3y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,237.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -408.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 363.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Fate Therapeutics 302.48 Mn 302.48 Mn - -1.12 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.12 Mn
Dec 31, 2025 -156,744.00
Sep 30, 2025 -328,819.00
Jun 30, 2025 -91,496.00
Mar 31, 2025 -981,647.00
Dec 31, 2024 -2.08 Mn
Sep 30, 2024 -480,236.00
Jun 30, 2024 -194,405.00
Mar 31, 2024 -425,237.00
Dec 31, 2023 -2.08 Mn
Sep 30, 2023 -798,537.00
Jun 30, 2023 -899,199.00
Mar 31, 2023 895,914.00
Dec 31, 2022 21,500.00
Sep 30, 2022 5,897.00
Jun 30, 2022 -60,991.00
Mar 31, 2022 26,151.00
Dec 31, 2021 -76,856.00
Sep 30, 2021 -6,486.00
Jun 30, 2021 96,489.00